PErmanent visual loss and cerebrovascular accidents in giant cell arteritis -: Predictors and response to treatment

被引:0
|
作者
González-Gay, MA
Blanco, R
Rodríguez-Valverde, V
Martínez-Taboada, VM
Delgado-Rodriguez, M
Figueroa, M
Uriarte, E
机构
[1] Hosp Univ M Valdecilla, Rheumatol Serv, Santander 39008, Spain
[2] Hosp Xeral Calde, Lugo, Spain
[3] Univ Cantabria, E-39005 Santander, Spain
[4] Hosp Nuestra Senora de Aranzazu, San Sebastian, Spain
来源
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 08期
关键词
D O I
10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the features and therapeutic response of visual manifestations and cerebrovascular accidents (CVA) in giant cell (temporal) arteritis (GCA) and to identify the predictors for permanent visual loss (VL) and CVA in GCA. Methods. Two hundred thirty-nine patients with biopsy-proven GCA were included in a retrospective multicenter study. Data on demographic, clinical, and laboratory features were collected. The predictors were identified by a forward stepwise nonconditional logistic regression analysis. Results. Visual involvement was observed in 69 patients, and 34 had permanent VL. The diagnostic delay since the onset of visual symptoms was longer in the 11 patients with bilateral VL. The interval to involvement of the second eye was 5 days. The predictors of permanent VL were transient VL, jaw claudication, normal levels of liver enzymes, and absence of constitutional syndrome. Partial improvement of visual acuity was observed in 8 patients. After adjustment for the treatment regimen (intravenous pulse methylprednisolone versus oral prednisone), early treatment (within the first day of VL) was the only predictor of improvement; CVA, observed in 8 patients, involved the vertebral-basilar territory in 4, CVA was more frequent in patients,vith visual symptoms, appearing shortly after VL (median 7 days) and despite appropriate therapy. Predictors of CVA were permanent VL and jaw claudication. Conclusion. In GCA, the risk of permanent VL is increased in patients with transient VL and/or jaw claudication, and decreased in those with elevated liver enzyme levels and/or constitutional syndrome. Partial therapeutic success is more probable if treatment is started within the first day of VL, CVA is more likely in patients with permanent VL and/or jaw claudication, often developing despite appropriate corticosteroid therapy.
引用
收藏
页码:1497 / 1504
页数:8
相关论文
共 50 条
  • [1] Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis
    Cruz-Machado, Ana Rita
    Barreira, Sofia
    Dourado, Eduardo
    Martinho, Joana
    Raimundo, Diana
    Brites, Luisa
    Assuncao, Helena
    Teixeira, Vitor
    Khmelinskii, Nikita
    Macieira, Carla
    da Silva, Jose A. P.
    Fonseca, Joao Eurico
    Ponte, Cristina
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [2] Predictors of cerebrovascular accidents in giant cell arteritis in a defined population
    Pego-Reigosa, R
    Garcia-Porrua, C
    Piñeiro, A
    Dierssen, T
    Llorca, J
    Gonzalez-Gay, MA
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (06) : S13 - S17
  • [3] Predictors of visual loss and cerebrovascular accidents in giant cell arteritis: comment on the article by Gonzalez-Gay et al
    Gonzalez, EB
    ARTHRITIS AND RHEUMATISM, 1999, 42 (04): : 825 - 826
  • [4] Predictors of Permanent Vision Loss in Giant Cell Arteritis
    Tucker, Susan M.
    Haas, Sara J.
    Rizvi, Tasneem Zaihra
    NEURO-OPHTHALMOLOGY, 2025, 49 (01) : 60 - 68
  • [5] Predictors of visual loss and cerebrovascular accidents in giant cell arteritis:: comment on the article by Gonzalez-Gay et al -: Reply
    Rodríguez-Valverde, V
    Delgado-Rodriguez, M
    Blanco, R
    Martínez-Taboada, VM
    González-Gay, MA
    Figueroa, M
    Uriarte, E
    ARTHRITIS AND RHEUMATISM, 1999, 42 (04): : 826 - 827
  • [6] CLINICAL SYMPTOMS AT GIANT CELL ARTERITIS DIAGNOSIS AS PREDICTORS OF PERMANENT VISUAL LOSS.
    Mestre-Torres, J.
    Escalante, B.
    Fonseca, E.
    Martinez-Zapico, A.
    Monteagudo, M.
    Abdilla, M.
    Conesa, M. Perez
    Tello, B. Gracia
    Prieto-Gonzalez, S.
    Fraile, G.
    Solans-Laque, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 379 - 379
  • [7] VISUAL INVOLVEMENT AND PERMANENT VISUAL LOSS IN GIANT CELL ARTERITIS: PREDICTIVE FACTORS
    Sanchez-Bilbao, L.
    Loricera, J.
    Moriano, C.
    Castaneda, S.
    Ferraz-Amaro, I.
    Narvaez, J.
    Aldasoro, V.
    Maiz, O.
    Melero, R.
    Villa-Blanco, I.
    Vela-Casasempere, P.
    Romero-Yuste, S.
    Callejas-Rubio, J. L.
    De Miguel, E.
    Galindez-Agirregoikoa, E.
    Sivera, F.
    Fernandez-Lopez, C.
    Galisteo, C.
    Sanchez-Martin, J.
    Calderon-Goercke, M.
    Hernandez, J. L.
    Gonzalez-Gay, M. A.
    Blanco, R.
    Tocilizumab In Giant Cell Arteritis
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 688 - 689
  • [8] Visual loss in giant cell arteritis
    Gordon, LK
    Levin, LA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (04): : 385 - 386
  • [9] Visual loss and giant cell arteritis
    Docken, WP
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (07): : 823 - 823
  • [10] Incidence of Cerebrovascular Accidents Among Patients with Giant Cell Arteritis.
    Tomasson, Gunnar
    Peloquin, Christine
    Love, Thorvardur
    Mohammad, Aladdin
    Zhang, Yuqing
    Choi, Hyon K.
    Merkel, Peter A.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S595 - S595